AstraZeneca made a reported $10 billion offer for Rhythm Pharmaceuticals, according to market reporting. The potential bid—rumored at $124 per share—puts pressure on Rhythm’s shareholders and signals renewed appetite for metabolic assets, particularly after Rhythm’s injectable weight-loss drug Imcivree gained additional approval for acquired hypothalamic obesity. In the same reporting context, Imcivree’s quarterly sales growth and a planned Phase 3 program in Prader-Willi syndrome were cited as key factors behind the attraction of Rhythm’s portfolio. Investors appeared to weigh the prospect of a larger strategic fit for AstraZeneca’s obesity pipeline, with Rhythm’s stock reacting sharply to the news. While the deal timing and structure remain unclear, the development emphasizes how major pharma continues to chase late-stage and label-expanding metabolic franchises, especially those with relatively differentiated mechanisms compared with GLP-1-heavy competitive landscapes. For biotech strategists and BD teams, the episode highlights the ongoing role of capital markets rumors in catalyzing valuation re-ratings—particularly for assets with growth levers like further indications and post-launch momentum.